Fig. 4: c-METis are identified as the most synergistic compounds in combination with AMPC to decrease ER+HER2+ MC cell viability. | Cell Death & Disease

Fig. 4: c-METis are identified as the most synergistic compounds in combination with AMPC to decrease ER+HER2+ MC cell viability.

From: Inhibition of TFF3 synergizes with c-MET inhibitors to decrease the CSC-like phenotype and metastatic burden in ER+HER2+ mammary carcinoma

Fig. 4

A Heatmap plot (https://hiplot.com.cn/) depicted the cell viability of MDA-MB-361 and BT474 cells post-treatment as Fraction affected (Fa) (Scale: Blue to Red). The cell viability of cells with the combination treatment of AMPC (0, 5, 10, or 20 µM) with 247 compounds for 3 days was assessed by AlamarBlue (BioChip, Beijing, China). B Synergistic pathways with AMPC were statistically analyzed. C Heatmap analysis of CI was performed on tyrosine kinase inhibitors (TKIs) exhibiting synergistic effects with AMPC in both MDA-MB-361 and BT474 cells. CI was calculated by Bliss independence method (Bliss CI = (EA + EB-EA×EB)/EAB). CI < 1 indicated a synergistic effect and a lower CI corresponds to higher synergy. D CI analysis was performed on compounds exhibiting synergistic effects with AMPC in both MDA-MB-361 and BT474 cells. CI < 1 indicated a synergistic effect and a lower CI corresponds to higher synergy. The red box highlighted the compounds that exhibited high synergy with AMPC in both MDA-MB-361 and BT474 cells.

Back to article page